FDG-PET Findings of Vertebral Compression Fractures in Osteoporosis: Preliminary Results

Schmitz, Alfred; Risse, J. H.; Textor, J.; Zander, David; Biersack, H.-J.; Schmitt, O.; Palmedo, Holger

doi:10.1007/s001980200103

Cited by 96 publications

(36 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…and based on medullary uptake, which is characteristic for malignant fractures (29,30). Fractures in two of our patients were caused by benign lesions, one was PET positive (SUV max.…”

Section: Discussionmentioning

confidence: 76%

The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT

Strobel

Exner

Stumpe

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

OBJECTIVE: To evaluate the value of a dedicated interpretation of the CT images in the differential diagnosis of benign vs. malignant primary bone lesions with 18 fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT). MATERIALS AND METHODS: In 50 consecutive patients (21 women, 29 men, mean age 36.9, age range 11-72) with suspected primary bone neoplasm conventional radiographs and 18F-FDG-PET/CT were performed. Differentiation of benign and malignant lesions was separately performed on conventional radiographs, PET alone (PET), and PET/CT with specific evaluation of the CT part. Histology served as the standard of reference in 46 cases, clinical, and imaging follow-up in four cases. RESULTS: According to the standard of reference, conventional 17 lesions were benign and 33 malignant. Sensitivity, specificity, and accuracy in assessment of malignancy was 85%, 65% and 78% for conventional radiographs, 85%, 35% and 68% for PET alone and 91%, 77% and 86% for combined PET/CT. Median SUV(max) was 3.5 for benign lesions (range 1.6-8.0) and 5.7 (range 0.8-41.7) for malignant lesions. In eight patients with bone lesions with high FDG-uptake (SUV(max) >or= 2.5) dedicated CT interpretation led to the correct diagnosis of a benign lesion (three fibrous dysplasias, two osteomyelitis, one aneurysmatic bone cyst, one fibrous cortical defect, 1 phosphaturic mesenchymal tumor). In four patients with lesions with low FDG-uptake (SUV(max) < 2.5) dedicated CT interpretation led to the correct diagnosis of a malignant lesion (three chondrosarcomas and one leiomyosarcoma). Combined PET/CT was significantly more accurate in the differentiation of benign and malignant lesions than PET alone (p = .039). There was no significant difference between PET/CT and conventional radiographs (p = .625). CONCLUSION: Dedicated interpretation of the CT part significantly improved the performance of FDG-PET/CT in differentiation of benign and malignant primary bone lesions compared to PET alone. PET/CT more commonly differentiated benign from malignant primary bone lesions compared with conventional radiographs, but this difference was not significant. The Additional Value of CT Images Interpretation in the Differential Diagnosis of Benign vs. Malignant Primary Bone Lesions with 18F- FDG-PET/CT Abstract ObjectiveTo evaluate the value of a dedicated interpretation of the CT images in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT. MethodsIn 50 consecutive patients (21 female, 29 male, mean age 36.9, age range 11 -72) with suspected primary bone neoplasm conventional radiographs and 18F-FDG-PET/CT were performed. Differentiation of benign and malignant lesions was separately performed on conventional radiographs, PET alone (PET) and PET/CT with specific evaluation of the CT part. Histology served as the standard of reference in 46 cases, clinical and imaging follow-up in four cases. ResultsAccording to the standard of reference conventional 17 lesions were benign and...

show abstract

“…and based on medullary uptake, which is characteristic for malignant fractures (29,30). Fractures in two of our patients were caused by benign lesions, one was PET positive (SUV max.…”

Section: Discussionmentioning

confidence: 76%

The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT

Strobel

Exner

Stumpe

et al. 2008

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…• Suspected spinal infection (spondylodiskitis or vertebral osteomyelitis, nonpostoperative) (24)(25)(26)(27)(28). • Evaluation of fever of unknown origin (FUO) (29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44), including true FUO (defined according to the criteria of Durack and Street (44)), postoperative fever and recurrent sepsis, immunodeficiency (both induced and acquired)-related FUO, neutropenic fever, and isolated acute-phase inflammation markers (persistently raised C-reactive protein and/or erythrocyte sedimentation rate).…”

Section: Common Clinical Indicationsmentioning

confidence: 99%

“…Therefore, SUV in this field should be used with caution in clinical practice. In a single study, though, in spondylodiskitis, an SUV cutoff greater than 3 has been suggested to avoid false-positive findings (26). This criterion, however, cannot be applied for other diseases.…”

Section: Quantitative Analysis (Suv)mentioning

confidence: 99%

EANM/SNMMI Guideline for¹⁸F-FDG Use in Inflammation and Infection

Buscombe²,

et al. 2013

View full text Add to dashboard Cite

“…Radiography, CT, MRI and bone scintigraphy may be nonspecific. Some reports suggest that 18F-FDG-PET may be useful in differentiating between malignant and benign fractures (88)(89)(90)(91), although there are only a few case reports regarding the clinical efficacy of fusion PET/CT on differentiating malignant from benign fractures (92)(93). Overlap of benign and malignant lesions has been shown (94).…”

Section: Differential Diagnosis Of Spinal Tumor By Petmentioning

confidence: 99%

Current Molecular Imaging of Spinal Tumors in Clinical Practice

Sandu

Pöpperl²,

Toubert

et al. 2011

Mol Med

View full text Add to dashboard Cite

Energy metabolism measurements in spinal cord tumors, as well as in osseous spinal tumors/metastasis in vivo, are rarely performed only with molecular imaging (MI) by positron emission tomography (PET). This imaging modality developed from a small number of basic clinical science investigations followed by subsequent work that influenced and enhanced the research of others. Apart from precise anatomical localization by coregistration of morphological imaging and quantification, the most intriguing advantage of this imaging is the opportunity to investigate the time course (dynamics) of disease-specific molecular events in the intact organism. Most importantly, MI represents one of the key technologies in translational molecular neuroscience research, helping to develop experimental protocols that may later be applied to human patients. PET may help monitor a patient at the vertebral level after surgery and during adjuvant treatment for recurrent or progressive disease. Common clinical indications for MI of primary or secondary CNS spinal tumors are: (i) tumor diagnosis, (ii) identification of the metabolically active tumor compartments (differentiation of viable tumor tissue from necrosis) and (iii) prediction of treatment response by measurement of tumor perfusion or ischemia. While spinal PET has been used under specific circumstances, a question remains as to whether the magnitude of biochemical alterations observed by MI in CNS tumors in general (specifically spinal tumors) can reveal any prognostic value with respect to survival. MI may be able to better identify early disease and to differentiate benign from malignant lesions than more traditional methods. Moreover, an adequate identification of treatment effectiveness may influence patient management. MI probes could be developed to image the function of targets without disturbing them or as treatment to modify the target's function. MI therefore closes the gap between in vitro and in vivo integrative biology of disease. At the spinal level, MI may help to detect progression or recurrence of metastatic disease after surgical treatment. In cases of nonsurgical treatments such as chemo-, hormone-or radiotherapy, it may better assess biological efficiency than conventional imaging modalities coupled with blood tumor markers. In fact, PET provides a unique possibility to correlate topography and specific metabolic activity, but it requires additional clinical and experimental experience and research to find new indications for primary or secondary spinal tumors.

show abstract

FDG-PET Findings of Vertebral Compression Fractures in Osteoporosis: Preliminary Results

Cited by 96 publications

References 12 publications

The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT

The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT

EANM/SNMMI Guideline for¹⁸F-FDG Use in Inflammation and Infection

Current Molecular Imaging of Spinal Tumors in Clinical Practice

Contact Info

Product

Resources

About

FDG-PET Findings of Vertebral Compression Fractures in Osteoporosis: Preliminary Results

Cited by 96 publications

References 12 publications

The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT

The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT

EANM/SNMMI Guideline for18F-FDG Use in Inflammation and Infection

Current Molecular Imaging of Spinal Tumors in Clinical Practice

Contact Info

Product

Resources

About

EANM/SNMMI Guideline for¹⁸F-FDG Use in Inflammation and Infection